Research priorities to move ctDNA assays into clinical decision making in early-stage breast cancer
Abstract
Circulating tumor DNA (ctDNA)-based Minimal Residual Disease (MRD) assays are increasingly utilised in early-stage breast cancer; but evidence for decision-making remains incomplete. The Breast International Group (BIG) and National Clinical Trials Network (NCTN) ctDNA working group identified research priorities to advance these assays toward clinical utility: clinical trial designs proving utility and affordability; validating ctDNA dynamics as surrogate endpoint; standardising assays; and evaluating patient-reported outcomes and equity. Prospective, randomised evidence remains essential before implementation.
// Source
Authors: Maria Coakley, Stefania Morganti, Catherine Alix‐Panabières, Philippe Bedard, gabriele zoppoli, Heather Parsons, Angela De Michele, Eric Winer, Antonio Wolff, David Cameron, Yara Abdou, Mariya Rozenblit, E. Shelley Hwang, Séamus O’Reilly, NU Lin, Michail Ignatiadis, David W. Cescon
Institutions: University of Pennsylvania, Johns Hopkins University, Harvard University, University of North Carolina at Chapel Hill, Duke University, Yale University, University of Edinburgh, Dana-Farber Cancer Institute, Princess Margaret Cancer Centre, Centre Hospitalier Universitaire de Montpellier, University of Genoa, Fred Hutch Cancer Center, Duke Cancer Institute, Cancer Trials Ireland, BC Cancer Agency, Institut Jules Bordet, Canadian Cancer Trials Group